Tardive Dyskinesia Treatment Market Trends and Analysis by Application, Vertical, Region, and Segment Forecast to 2029

 Crafted for informed planning, this report explores the forces reshaping the tardive dyskinesia treatment market and what they mean for business leaders.

 

 How Large Will The Tardive Dyskinesia Treatment Market Be By 2025?
 The tardive dyskinesia treatment market size has grown strongly in recent years. It will grow from $2.40 billion in 2024 to $2.61 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to increasing use of antipsychotic medications, growing awareness of drug-induced movement disorders, rising incidence of schizophrenia and bipolar disorders, increasing off-label use of antipsychotics, and growing geriatric population using psychotropic drugs.
 
 The tardive dyskinesia treatment market size is expected to see strong growth in the next few years. It will grow to $3.61 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to growing demand for safer antipsychotic therapies, rising awareness through advocacy and education campaigns, growing focus on personalized mental health treatments, rising healthcare spending on neurological and psychiatric disorders, and a growing number of psychiatric patients under long-term therapy. Major trends in the forecast period include developing neuroprotective strategies, developing dual-action therapies, integration of real-world evidence (RWE) in drug evaluation, integration of digital biomarkers, and innovation in non-dopaminergic therapeutics.
 
 Get your free sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=27431&type=smp
 
 What Are Key Factors Driving The Demand In The Global Tardive Dyskinesia Treatment Market?
 The increasing prevalence of psychiatric disorders is expected to propel the growth of the tardive dyskinesia treatment market going forward. Psychiatric disorders refer to a wide range of mental health conditions that affect a person’s mood, thinking, behavior, and overall functioning, often requiring clinical diagnosis and treatment. The prevalence of psychiatric disorders is growing due to rising stress and lifestyle pressures resulting from high workloads, social isolation, and limited time for self-care. Tardive dyskinesia treatment helps manage involuntary movement symptoms, improving overall treatment outcomes and quality of life for individuals with psychiatric disorders who require long-term antipsychotic medication. For instance, in March 2024, according to the House of Commons Library, a UK-based research and information service, in 2022, the proportion of 17- to 19-year-olds with a probable mental disorder increased from 17% in 2021 to 26%. Therefore, the increasing prevalence of psychiatric disorders is driving the growth of the tardive dyskinesia treatment market.
 
 Comparative Analysis Of Leading Tardive Dyskinesia Treatment Market Segments
 The tardive dyskinesia treatment market covered in this report is segmented
 
 1) By Treatment Type: Medications, Botulinum Toxin Injections, Deep Brain Stimulation, Other Treatment Types
 2) By Drug: Valbenazine, Amantadine, Tetrabenazine, Clonazepam, Other Drugs
 3) By Route Of Administration: Oral Administration, Injection, Transdermal Patches
 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
 5) By End-Users: Hospitals, Specialty Clinics, Other End-Users
 
 Subsegments:
 1) By Medications: Antipsychotic Medications, Benzodiazepines, Dopamine-Depleting Agents, Anticholinergic Agents
 2) By Botulinum Toxin Injections: Facial Muscle Injections, Neck Muscle Injections, Limb Muscle Injections, Customized Injection Protocols
 3) By Deep Brain Stimulation: Subthalamic Nucleus Stimulation, Globus Pallidus Interna Stimulation, Thalamic Stimulation, Multi-Target Stimulation
 4) By Other Treatment Types: Supportive Therapies, Cognitive Behavioral Therapy, Physical Rehabilitation, Emerging Experimental Treatments
 
 What Are The Key Trends Shaping The Tardive Dyskinesia Treatment Industry?
 Major companies operating in the tardive dyskinesia treatment market are focusing on developing innovative drugs, such as sprinkle capsule formulations, to improve medication adherence for patients with swallowing difficulties. Sprinkle capsule formulations are medications designed to be opened and sprinkled onto soft food, making them easier to swallow for patients with dysphagia or difficulty taking whole capsules. For instance, in July 2024, Neurocrine Biosciences Inc., a US-based biotechnology company, launched Ingrezza sprinkle (valbenazine) capsules, the leading prescribed vesicular monoamine transporter 2 (VMAT2) inhibitor for treating adults with tardive dyskinesia and chorea associated with Huntington’s disease. This VMAT2 inhibitor works by regulating dopamine levels in the brain to help manage involuntary movements. The medication is available as a once-daily oral capsule, including a sprinkle formulation designed to ease administration for patients who have difficulty swallowing.
 
 Who Are The Prominent Players In The Tardive Dyskinesia Treatment Business?
 Major companies operating in the tardive dyskinesia treatment market are AbbVie Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Jazz Pharmaceuticals plc, Kyowa Kirin Co Ltd., H. Lundbeck A/S, Zydus Lifesciences Limited, Neurocrine Biosciences Inc., Luye Pharma Group Ltd., Acadia Pharmaceuticals Inc., Upsher-Smith Laboratories LLC, SteriMax Inc., Adamas Pharmaceuticals Inc., ChemWerth Inc, Sunovion Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, Synnat Pharma Pvt. Ltd, LGM Pharma LLC, and SOM Biotech S.A. 
 
 View the full tardive dyskinesia treatment market report here:
 https://www.thebusinessresearchcompany.com/report/tardive-dyskinesia-treatment-global-market-report
 
 Which Region Is Expected To Lead The Tardive Dyskinesia Treatment Market By 2025?
 North America was the largest region in the tardive dyskinesia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tardive dyskinesia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company